We review your portfolio and open untapped markets for your pharma, biotech & medtech assets.
While core established markets remain valuable, they are increasingly exposed to regulatory, reimbursement, and competitive pressures. Emerging markets are gaining momentum — driven by strong demand, open competition, and faster access opportunities.
By accelerating time-to-revenue and leveraging our plug-and-play model, we help you secure scalable and sustainable growth.
Reduce core market dependency
High demand, innovation-driven, fewer competitors
Fast-track launches, accelerate impact
Maximizing value, minimizing risk
Efficient processes, and a high-performing team.
Where you are structured to succeed.
Expand internationally without the need for significant internal investment.
Our insights are built on real data, field intelligence, and tangible execution.
We anticipate market shifts, identify new revenue levers, and transform analysis into concrete market growth.
Through our proactive, hands-on approach, BIOINNOVEX delivers measurable impact — securing partnerships, accelerating access, and generating additional value across every stage of expansion.
Tailored programs to unlock your global potential.
We help investment funds unlock the global potential of their biotech and medtech portfolio through market due diligence, scalability assessments, and local access strategies — accelerating growth while reducing operational and regulatory risks.
We identify high-potential markets, secure strategic access, and coordinate local execution to help pharma and biotech companies achieve scalable, sustainable growth.
For companies focused on rare diseases aiming to broaden patient access globally, we oversee registration, coordinate logistics, and build strategic partnerships to deliver compliant, efficient, and high-impact product launches.
For companies with established or registered products we open new markets, revitalize sales, and turn mature assets into fresh revenue streams.
A seamless transition from strategy to execution, delivering measurable results on the ground.
Strategic mapping, opportunity screening, business case per region, risk assessment
Market access & regulatory pathways, partner identification & negotiations, commercial coordination
On-the-ground execution with trusted partners, performance monitoring, ensuring sustainable sales
Accelerating your time-to-revenue
Transparent execution
Customized market selection
Adapted to your level of involvement
Core focus: Eastern Europe, Turkey, Middle East, selected Africa/Asia, Australia
References upon request
French biotech company, turnover up to $M500
Launch of rare disease therapies through targeted patient screening and national reimbursement programs.
US pharm / medtech company, turnover over $1B
Business operations set up across selected markets, kick-off of operations in Israel, Nigeria, Namibia.
French pharma company, turnover up to $M500
Operations set up in Russia, Greece & Turkey, 6 product launches, market access strategy.
US medtech & pharmaceutical company, turnover $M500
Business expansion in South Korea & Australia through local partnerships and a sales force.
French biopharma group, turnover over $1B
Assessment for licensing opportunities for orphan products and partnerships for a rare disease product.
Swiss pharma company, turnover over $1B
Go-to-Market strategy, selection of local distributors, commercial operations across small countries.
French Pharma & IVD company, turnover over M$500
Audit of distribution models across CIS markets. Optimized distribution strategies and improved operational efficiency.
Spanish pharma company, turnover over $1B
Go-to-market strategy, local regulatory approval and support, local commercial organisation set up.
Swiss pharma company, turnover around $M500
Restructured operations in Russia & CIS, transitioning from distributors to direct presence through a new go-to-market strategy.
Contact us to explore how we can turn your portfolio into global revenue.
www.bioinnovex.com